This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ebert, O. Articles by Woo, S. L. C. Search for Related Content PubMed PubMed Citation Articles by Ebert, O. Articles by Woo, S. L. C.

Syncytia Induction Enhances the Oncolytic Potential of Vesicular Stomatitis Virus in Virotherapy for Cancer

¹ Carl C. Icahn Center for Gene Therapy and Molecular Medicine and ² Department of Microbiology, Mount Sinai School of Medicine, New York, New York

Vesicular stomatitis virus (VSV) selectively replicates in tumor but not in normal cells and is being developed as an oncolytic agent for cancer therapy. Here we report the construction of a recombinant VSV capable of inducing syncytia formation between tumor cells through membrane fusion at neutral pH, which led to enhanced oncolytic properties against multifocal hepatocellular carcinoma (HCC) in the livers of immunocompetent rats. Recombinant VSV vectors were constructed by insertion into their genome a transcription unit expressing a control or fusion protein derived from Newcastle disease virus. In vitro characterization of the recombinant fusogenic VSV vector on human and rat HCC cells showed extensive syncytia formation and significantly enhanced cytotoxic effects. In vivo, administration of fusogenic VSV into the hepatic artery of Buffalo rats bearing syngeneic multifocal HCC lesions in their livers resulted in syncytia formation exclusively within the tumors, and there was no collateral damage to the neighboring hepatic parenchyma. The fusogenic VSV also conferred a significant survival advantage over a nonfusogenic control virus in the treated animals (P = 0.0078, log-rank test). The results suggest that fusogenic VSV can be developed into an effective and safe therapeutic agent for cancer treatment in patients, including those with multifocal HCC in the liver.

This article has been cited by other articles:

				M. D. Gainey, M. J. Manuse, and G. D. Parks A Hyperfusogenic F Protein Enhances the Oncolytic Potency of a Paramyxovirus Simian Virus 5 P/V Mutant without Compromising Sensitivity to Type I Interferon J. Virol., October 1, 2008; 82(19): 9369 - 9380. [Abstract] [Full Text] [PDF]

				A. Vigil, M.-S. Park, O. Martinez, M. A. Chua, S. Xiao, J. F. Cros, L. Martinez-Sobrido, S. L.C. Woo, and A. Garcia-Sastre Use of Reverse Genetics to Enhance the Oncolytic Properties of Newcastle Disease Virus Cancer Res., September 1, 2007; 67(17): 8285 - 8292. [Abstract] [Full Text] [PDF]

				D. F. Gaddy and D. S. Lyles Oncolytic Vesicular Stomatitis Virus Induces Apoptosis via Signaling through PKR, Fas, and Daxx J. Virol., March 15, 2007; 81(6): 2792 - 2804. [Abstract] [Full Text] [PDF]

				X. Fu, L. Tao, M. Li, W. E. Fisher, and X. Zhang Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus. Clin. Cancer Res., May 15, 2006; 12(10): 3152 - 3157. [Abstract] [Full Text] [PDF]

				F. Errington, A. Bateman, T. Kottke, J. Thompson, K. Harrington, A. Merrick, P. Hatfield, P. Selby, R. Vile, and A. Melcher Allogeneic Tumor Cells Expressing Fusogenic Membrane Glycoproteins as a Platform for Clinical Cancer Immunotherapy Clin. Cancer Res., February 15, 2006; 12(4): 1333 - 1341. [Abstract] [Full Text] [PDF]

				K. Shinozaki, O. Ebert, A. Suriawinata, S. N. Thung, and S. L. C. Woo Prophylactic Alpha Interferon Treatment Increases the Therapeutic Index of Oncolytic Vesicular Stomatitis Virus Virotherapy for Advanced Hepatocellular Carcinoma in Immune-Competent Rats J. Virol., November 1, 2005; 79(21): 13705 - 13713. [Abstract] [Full Text] [PDF]